Clinical Chemistry, Malmö
951 – 960 of 1289
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2003
-
Mark
Probing plasma clearance of the thrombin-antithrombin complex with a monoclonal antibody against the putative serpin-enzyme complex receptor-binding site.
(
- Contribution to journal › Article
-
Mark
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable
(
- Contribution to journal › Article
-
Mark
Stabilyte (TM) tubes that contain strongly acidic citrate prevent in vitro complex formation between activated protein C and protein C inhibitor
(
- Contribution to journal › Letter
-
Mark
Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues
(
- Contribution to journal › Article
-
Mark
Factor V Leiden in pregnancies complicated by placental abruption
(
- Contribution to journal › Article
-
Mark
Prevention of thrombosis following deep arterial injury in rats by bovine activated protein C requiring co-administration of bovine protein S.
(
- Contribution to journal › Article
-
Mark
Role of CCP2 of the C4b-binding protein beta-chain in protein S binding evaluated by mutagenesis and monoclonal antibodies.
(
- Contribution to journal › Article
-
Mark
Innovators in urology : Introduction
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
(
- Contribution to journal › Article
-
Mark
Activated protein C resistance (FVLeiden) and thrombosis: factor V mutations causing hypercoagulable states
(
- Contribution to journal › Scientific review